Alterity Therapeutics Limited - American Depositary Shares (ATHE)
ATHE moved a median of -0.28% 30 minutes after news, and +0.25% by the close. How ATHE actually reacts to news — the realized, point-in-time move the market made, measured across 207 labeled events over the last three years with zero look-ahead.
ATHE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 28% | 170 |
| 30-min | -0.28% | 35% | 195 |
| 60-min | 0.00% | 46% | 203 |
| to close | +0.25% | 50% | 203 |
| Middle 50% of ATHE reactions | -2.28% to +1.25% |
|---|---|
| Median reaction (30-min) | -0.28% |
| Measured reactions | 207 |
Half of all Alterity Therapeutics Limited - American Depositary Shares news events land between -2.28% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ATHE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ATHE's baseline. Nothing else.
Recent ATHE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference | Press release | GlobeNewswire | — | -2.35% | |
| Form 6-K ALTERITY THERAPEUTICS For: Oct 31 | SEC filing · Form 6-K | SEC EDGAR | — | -2.35% | |
| Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders | Press release | GlobeNewswire | -3.03% | -2.42% | |
| Form 6-K ALTERITY THERAPEUTICS For: Oct 31 | SEC filing · Form 6-K | SEC EDGAR | -3.03% | -2.42% | |
| Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 | Press release | GlobeNewswire | +0.00% | -0.66% | |
| Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 | Press release | GlobeNewswire | +0.80% | -1.80% | |
| Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference | Press release | GlobeNewswire | — | +4.11% | |
| Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update | Press release | GlobeNewswire | +2.38% | +7.02% | |
| Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026 | Press release | GlobeNewswire | — | +4.40% | |
| Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy | Press release | GlobeNewswire | -2.90% | -6.47% | |
| Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy | Press release | GlobeNewswire | +4.27% | +7.79% | |
| Form 6-K ALTERITY THERAPEUTICS For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +1.38% | +0.25% | |
| Form 6-K ALTERITY THERAPEUTICS For: May 31 | SEC filing · Form 6-K | SEC EDGAR | -0.86% | +1.48% | |
| Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy | Press release | GlobeNewswire | — | -0.23% | |
| Form 6-K ALTERITY THERAPEUTICS For: May 31 | SEC filing · Form 6-K | SEC EDGAR | — | -0.23% | |
| Form 6-K ALTERITY THERAPEUTICS For: May 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.33% | |
| Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy | Press release | GlobeNewswire | +0.00% | -2.44% | |
| Form 6-K ALTERITY THERAPEUTICS For: May 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.44% | |
| Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 | Press release | GlobeNewswire | +0.44% | +2.86% | |
| Form 6-K ALTERITY THERAPEUTICS For: May 31 | SEC filing · Form 6-K | SEC EDGAR | +0.44% | +2.86% | |
| Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update | Press release | GlobeNewswire | -0.66% | -0.87% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | -0.66% | -0.87% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +2.84% | +0.89% | |
| Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy | Press release | GlobeNewswire | +0.00% | -3.75% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -3.75% | |
| Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology | Press release | GlobeNewswire | -0.63% | -5.42% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | -0.63% | -5.42% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -5.73% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +0.67% | +14.44% | |
| Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors | Press release | GlobeNewswire | +0.07% | +11.75% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +0.07% | +11.75% | |
| Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting | Press release | GlobeNewswire | — | +3.78% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +1.33% | +5.58% | |
| Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy | Press release | GlobeNewswire | +0.27% | +1.64% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +0.27% | +1.64% | |
| Form 6-K ALTERITY THERAPEUTICS For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | — | +2.14% | |
| Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program | Press release | GlobeNewswire | +1.67% | +8.18% | |
| Form 6-K ALTERITY THERAPEUTICS For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +1.67% | +8.18% | |
| Form 6-K ALTERITY THERAPEUTICS For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.60% | -5.67% | |
| Form 6-K ALTERITY THERAPEUTICS For: Mar 19 | SEC filing · Form 6-K | SEC EDGAR | — | +0.00% | |
| Form 6-K ALTERITY THERAPEUTICS For: Mar 13 | SEC filing · Form 6-K | SEC EDGAR | +0.03% | +0.00% | |
| Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit | Press release | GlobeNewswire | +0.00% | +5.97% | |
| Form 6-K ALTERITY THERAPEUTICS For: Mar 09 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +5.97% | |
| Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor | Press release | GlobeNewswire | — | -0.29% | |
| Form 6-K ALTERITY THERAPEUTICS For: Mar 04 | SEC filing · Form 6-K | SEC EDGAR | — | -0.29% | |
| Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments | Press release | GlobeNewswire | — | +3.60% | |
| Form 6-K ALTERITY THERAPEUTICS For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | — | +3.25% | |
| Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update | Press release | GlobeNewswire | — | -1.25% | |
| Form 6-K ALTERITY THERAPEUTICS For: Jan 30 | SEC filing · Form 6-K | SEC EDGAR | — | -1.25% | |
| Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 | Press release | GlobeNewswire | -0.33% | +6.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ATHE section they belong to.
Where else ATHE is measured.
ATHE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alterity Therapeutics Limited - American Depositary Shares's median reaction calculated?
Every labeled ATHE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 207 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of ATHE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ATHE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.